The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

Pancreatic cancer is a stubborn and difficult cancer to treat. In fact, it has the highest death rate of all major cancers. Now, researchers have found a new treatment protocol may help some people ...

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

Data suggest that neoadjuvant immune checkpoint inhibitor (ICI) therapy improves outcomes in patients with early-stage triple-negative breast cancer, but adjuvant ICI therapy does not.

Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...

The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

Population-based cohort study identifies better treatment objectives for women with advanced-stage ovarian cancer.

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.